ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q2 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,712,158 | +24.8% | 431,546 | +41.3% | 0.05% | +31.6% |
| Q2 2023 | $9,386,951 | -52.3% | 305,366 | -44.1% | 0.04% | -56.3% |
| Q1 2023 | $19,698,826 | +87.2% | 546,734 | +105.3% | 0.09% | +70.6% |
| Q4 2022 | $10,524,136 | +55.8% | 266,299 | +58.3% | 0.05% | +45.7% |
| Q3 2022 | $6,757,000 | -36.5% | 168,173 | -33.6% | 0.04% | -32.7% |
| Q2 2022 | $10,647,000 | -7.2% | 253,266 | -14.0% | 0.05% | +15.6% |
| Q1 2022 | $11,470,000 | +57.9% | 294,399 | +61.5% | 0.04% | +66.7% |
| Q4 2021 | $7,266,000 | -41.0% | 182,331 | -46.5% | 0.03% | -51.8% |
| Q3 2021 | $12,323,000 | -69.0% | 340,979 | -64.8% | 0.06% | -68.0% |
| Q2 2021 | $39,761,000 | +2.4% | 970,006 | +9.0% | 0.18% | -0.6% |
| Q1 2021 | $38,811,000 | +196.9% | 889,751 | +240.7% | 0.18% | +214.3% |
| Q4 2020 | $13,070,000 | – | 261,145 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |